Document Detail


Compound ion salt, a novel low-sodium salt substitute: from animal study to community-based population trial.
MedLine Citation:
PMID:  19661926     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Salt restriction, an important approach for primary and secondary prevention of hypertension, is undermined by unsatisfactory adherence. A salt-restriction study tested the efficacy and safety of a compound ion salt (CISalt) with low sodium content in an animal model and in a community-based population.
METHODS: In part 1, 8-week-old male spontaneously hypertensive rats (SHRs) were fed 1% CISalt in the study group and 8% or 1% normal salt (NSalt) in controls (n = 10 each) for 12 weeks. Blood pressure (BP) and urinary electrolytes were measured every 3 weeks. After 12 weeks, collagen deposition in the heart and kidney and the levels of angiotensin II (Ang II) and nitric oxide (NO) in plasma and renal cortex were measured. In part 2, a single-blind, randomized, 6-month controlled trial with CISalt was conducted in 248 persons (age >or=65 years) in 10 rural communities. Plasma renin activity and Ang II were included in blood and urinary measures at baseline and 6 months.
RESULTS: Reduced BP urinary protein excretion and reduced collagen in the heart and kidneys were significantly different in animals fed CISalt compared to controls. In human studies, at 6 months, mean systolic BP (SBP) was decreased by 9.6 mm Hg (95% confidence interval (CI): 13.1 to 6.1, P < 0.001) and diastolic BP (DBP) by 5.3 mm Hg (95% CI: 7.9 to 2.6, P < 0.001), respectively, compared to controls; urinary sodium excretion also decreased by 67.4 mmol/24 h (95% CI: 84.8 to 50.0, P < 0.001), and plasma renin activity was slightly increased by 0.19 ng/ml/h (95% CI: 0.04-0.33, P = 0.013). No adverse cardiovascular events were reported.
CONCLUSIONS: In these studies, CISalt lowered BP and showed end-organ protection in hypertensive animals and BP reduction in humans. CISalt appears to be a safe and acceptable strategy to reduce BP.
Authors:
Xin Zhou; Jun-Xiang Liu; Rui Shi; Ning Yang; Dong-Lin Song; Wei Pang; Yu-Ming Li
Related Documents :
8026556 - Cardiovascular effects of felodipine are not antagonized by dietary salt.
17237246 - Morphological and biochemical characterization of remodeling in aorta and vena cava of ...
8747306 - Central gabaergic mechanisms are defective in salt-induced hypertension in borderline h...
10226336 - Nitric oxide, salt sensitivity, and cardiorenal injury in hypertension.
1984886 - In vitro and in vivo effects within the coronary sinus of nonarcing and arcing shocks u...
15760856 - Incorrect needle position during lumbar epidural steroid administration: inaccuracy of ...
Publication Detail:
Type:  Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial     Date:  2009-08-06
Journal Detail:
Title:  American journal of hypertension     Volume:  22     ISSN:  1941-7225     ISO Abbreviation:  Am. J. Hypertens.     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-08-24     Completed Date:  2009-12-03     Revised Date:  2011-06-30    
Medline Journal Info:
Nlm Unique ID:  8803676     Medline TA:  Am J Hypertens     Country:  United States    
Other Details:
Languages:  eng     Pagination:  934-42     Citation Subset:  IM    
Affiliation:
Institute of Cardiovascular Disease and Division of Cardiology, Pingjin Hospital, Medical College of the Chinese People's Armed Police Forces, Tianjin, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Animals
Blood Pressure / drug effects*
Calcium Carbonate / adverse effects,  therapeutic use
Calcium Citrate / adverse effects,  therapeutic use
Electrolytes / urine
Female
Folic Acid / adverse effects,  therapeutic use*
Humans
Hypertension / drug therapy*
Kidney / drug effects,  pathology
Male
Middle Aged
Myocardium / pathology
Potassium Chloride / adverse effects,  therapeutic use*
Rats
Rats, Inbred SHR
Sodium Chloride / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Electrolytes; 471-34-1/Calcium Carbonate; 5785-44-4/Calcium Citrate; 59-30-3/Folic Acid; 7447-40-7/Potassium Chloride; 7647-14-5/Sodium Chloride

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-...
Next Document:  Family-based randomized trial to detect effects on blood pressure of a salt substitute containing po...